Department of Oncology, University of Cambridge, Hutchison/Medical Research Council (MRC) Research Centre, Cambridge, UK.
Pediatr Blood Cancer. 2012 Apr;58(4):649-51. doi: 10.1002/pbc.23329. Epub 2011 Sep 15.
Neuroblastoma (NBL) is a pediatric tumor of infancy derived from precursor cells of the sympathetic nervous system. Clinicians and researchers in developmental biology and genetics recently met to facilitate meaningful crosstalk and to discuss considerable progress made in the clinical treatment and basic biology of NBL. For instance, discoveries in familial NBL have identified genetic aberrations in Phox2b and Alk that predispose to NBL, while advances in epigenetics and MYCN regulation have also offered insight into NBL pathogenesis and future treatment. Moreover, novel therapeutic avenues are also being explored, including targeted immunotherapies, and innovative radiotherapeutic and chemotherapeutic approaches. This multi-disciplinary meeting was convened to aid the transfer of new biological findings into the clinic and to use clinical advances to inform the basic biological understanding of this devastating disease.
神经母细胞瘤(NBL)是一种起源于交感神经系统前体细胞的婴儿期小儿肿瘤。临床医生和发育生物学与遗传学研究人员最近举行了会议,以促进有意义的交流,并讨论 NBL 的临床治疗和基础生物学方面取得的相当大的进展。例如,家族性 NBL 的发现确定了 Phox2b 和 Alk 中的遗传异常,这些异常易导致 NBL,而表观遗传学和 MYCN 调控方面的进展也为 NBL 的发病机制和未来的治疗提供了新的思路。此外,还在探索新的治疗途径,包括靶向免疫疗法以及创新的放射治疗和化学治疗方法。召开本次多学科会议是为了帮助将新的生物学发现转化为临床应用,并利用临床进展为了解这种毁灭性疾病的基础生物学提供信息。